US Pharma MarketingThe deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
Novartis to acquire ADC developer in a deal worth up to $1.5B
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
Source: BioPharma Dive